The use of chondroprotectors (SYSADOA) would enable the NHS to avoid around 20,000 adverse effects per year, with an economic saving of more than 40 million Euros over three years
- The report issued by the consultancy Health Value analyzes the health and budgetary impact of the treatment of knee osteoarthritis with chondroitin sulfate, a drug pertaining to the slow-acting chondroprotective group
- Chondroprotectors are determinant as long-term medication with great therapeutic advantages
Reig Jofre, a pharmaceutical company listed on the Spanish continuous market, today presented the Budget and Health Impact Report prepared by the consultancy Health Value. The presentation was given by Mr. Carlos Rubio, director of the consultancy Health Value and an expert in Pharmacoeconomics, Dr. Miguel Bernad, Rheumatology Specialist at La Paz University Hospital in Madrid and Dr. Marta Herrero, Senior Manager Innovation and Pipeline Management at Reig Jofre.
Osteoarthritis is the most frequent rheumatic disease in Spain and will become the fourth cause of disability in the world in 2020, according to the WHO. It is a serious disease that increases the risk of death by 20%.
Chondroitin Sulfate and Glucosamine (SYSADOA (English Syntomatic Slow Action Drugs for Osteoarthiritis)) are a group of slow-acting drugs approved by the Spanish Agency of Medicines for the treatment of osteoarthritis, a disease afflicting some 7 million Spaniards. They are an alternative of great therapeutic utility and enable reductions in pain and improvements in functional capacity. They are safe drugs, especially for those patients with comorbidities (other pathologies) for which the use of analgesics or anti-inflammatories may be contraindicated.